93% Improvementin Cancer Detection Over Standard of Care.
77% cancer detection rate with Promaxo versus 40% with standard-of-care TRUS biopsy1. 23% more clinically significant cancers identified2. 33% upstaging at diagnosis — leading to better treatment decisions and more targeted treatment plans2,4.
Promaxo vs. Standard of Care:
The Numbers.
From the physicians using the platform.
The Promaxo MRI has reduced my patients' discomfort level during the biopsy.
With dedicated 2026 CPT codes supporting Promaxo MRI-Guided procedures, the economics now match the level of care we provide!
30+ peer-reviewed publications.
Clinical and methodological publications describing low-field, point-of-care MRI-Guided prostate biopsy and treatment outcomes. Thousands of patients treated worldwide.
Accurate Prostate Biopsies Using Low-Field Portable Interventional MRI in an Ambulatory Surgical Center
Price et al. · IPCU · 2024
Feasibility and preliminary clinical tolerability of low-field MRI-guided prostate biopsy
Sze et al. · The Prostate, 83(7), 656–662 · 2023
Cost-efficient analysis of a portable low-field MRI system for prostate cancer diagnosis
Sze et al. · Frontiers in Urology, 2:966862 · 2022
Advantageous Detection of Significant Prostate Cancer Using a Low-Field, Office-Based MRI System
Chiragzada et al. · Cureus, 14(12):e32105 · 2022
Managing Patients With Unlabeled Passive Implants on MR Systems Operating Below 1.5T
Methodological guidance · 2024